Xact Kapitalforvaltning’s Heron Therapeutics HRTX Stock Holding History

Xact Kapitalforvaltning’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$153K	Hold	13,000	–	–	﹤0.01%	1249
2019 Q4	$306K	Hold	13,000	–	–	0.01%	1233
2019 Q3	$240K	Hold	13,000	–	–	﹤0.01%	1313
2019 Q2	$242K	Hold	13,000	–	–	0.01%	1325
2019 Q1	$318K	Hold	13,000	–	–	0.01%	1186
2018 Q4	$337K	Buy	13,000 +3,100	+31%	+$85.2K	0.01%	1159
2018 Q3	$313K	Hold	9,900	–	–	0.01%	1341
2018 Q2	$385K	Sell	9,900 -800	-7%	-$25.5K	0.01%	1145
2018 Q1	$295K	Buy	+10,700	New	+$243K	0.01%	1257

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Xact Kapitalforvaltning's HRTX Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Heron Therapeutics (HRTX) position steady in Q1 2020 at 13,000 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #1249.

Xact Kapitalforvaltning first reported a position in HRTX in Q1 2018 and has held it in 9 quarters since. The position peaked at $385K in Q2 2018. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

Xact Kapitalforvaltning held 13,000 shares of Heron Therapeutics worth $153K as of Q1 2020.
Xact Kapitalforvaltning left its Heron Therapeutics share count unchanged in Q1 2020.
Heron Therapeutics made up ﹤0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #1249 holding.
Xact Kapitalforvaltning first reported a position in Heron Therapeutics in Q1 2018 and has held it in 9 quarters since.
Xact Kapitalforvaltning's Heron Therapeutics position peaked at $385K in Q2 2018.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.